Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Lithium Americas Corp — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.6 (market cap $6.04B), while Lithium Americas Corp trades at $2.36 (market cap $850.38M). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 7.1× Lithium Americas Corp's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Lithium Americas Corp for 27 Days on average.
| IOVA | LAC | |
|---|---|---|
Market Cap | $6.04B | $850.38M |
Volume | 14,805,993 | 8,804,637 |
Sector | Health | Basic Materials |
52-Week High | $14.82 | $10.05 |
52-Week Low | $1.81 | $2.36 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $5.97B | $1.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lithium Americas (LAC) trades at $2.35, down 2.49% on the day, with a bearish technical outlook despite recent earnings beats. The company shows negative profitability metrics (ROE -9.56%, ROA -3.99%) and zero revenue in 2025, though construction progress at Thacker Pass provides potential upside. Analyst consensus is mixed with 7 buy and 8 hold ratings, pointing to a $4.00 price target representing 70% upside from current levels.
LAC presents a high-risk, high-reward opportunity as it transitions from development to execution phase. The primary investment thesis hinges on successful Thacker Pass development and lithium price recovery, while key risks include project execution challenges, negative cash flow from operations, and volatile lithium markets. Current valuation at 0.6x book value suggests potential undervaluation if operational milestones are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
